Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2-B as second-line therapy for relapsed/refractory mantle cell lymphoma
2011-005461-21Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, lenalidomide, rituximab in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Started Jun 2012; status: completed.
02
Drugs
bendamustinelenalidomiderituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2011-005461-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005461-21.